First Time Loading...

ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 3.16 USD 0.64% Market Closed
Updated: Jun 13, 2024
Have any thoughts about
ADC Therapeutics SA?
Write Note

Intrinsic Value

ADCT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

ADC Therapeutics SA is a clinical-stage biotechnology company. [ Read More ]

The intrinsic value of one ADCT stock under the Base Case scenario is 5.86 USD. Compared to the current market price of 3.16 USD, ADC Therapeutics SA is Undervalued by 46%.

Key Points:
ADCT Intrinsic Value
Base Case
5.86 USD
Undervaluation 46%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ADC Therapeutics SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ADCT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ADC Therapeutics SA

Current Assets 290.2m
Cash & Short-Term Investments 234.3m
Receivables 23.2m
Other Current Assets 32.7m
Non-Current Assets 17.8m
Long-Term Investments 930k
PP&E 15.8m
Other Non-Current Assets 986k
Current Liabilities 63m
Accounts Payable 14.3m
Accrued Liabilities 28.2m
Other Current Liabilities 20.5m
Non-Current Liabilities 439.4m
Long-Term Debt 423.2m
Other Non-Current Liabilities 16.2m
Efficiency

Earnings Waterfall
ADC Therapeutics SA

Revenue
121.4m USD
Cost of Revenue
-6m USD
Gross Profit
115.4m USD
Operating Expenses
-391.9m USD
Operating Income
-276.5m USD
Other Expenses
-105.1m USD
Net Income
-381.6m USD

Free Cash Flow Analysis
ADC Therapeutics SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ADCT Profitability Score
Profitability Due Diligence

ADC Therapeutics SA's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

33/100
Profitability
Score

ADC Therapeutics SA's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

ADCT Solvency Score
Solvency Due Diligence

ADC Therapeutics SA's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Positive Net Debt
Long-Term Solvency
40/100
Solvency
Score

ADC Therapeutics SA's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ADCT Price Targets Summary
ADC Therapeutics SA

Wall Street analysts forecast ADCT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADCT is 10.2 USD with a low forecast of 8.08 USD and a high forecast of 13.65 USD.

Lowest
Price Target
8.08 USD
156% Upside
Average
Price Target
10.2 USD
223% Upside
Highest
Price Target
13.65 USD
332% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ADCT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ADCT Price
ADC Therapeutics SA

1M 1M
-25%
6M 6M
+88%
1Y 1Y
+30%
3Y 3Y
-86%
5Y 5Y
-89%
10Y 10Y
-89%
Annual Price Range
3.16
52w Low
0.4681
52w High
5.29
Price Metrics
Average Annual Return -37.33%
Standard Deviation of Annual Returns 45.24%
Max Drawdown -99%
Shares Statistics
Market Capitalization 304.1m USD
Shares Outstanding 96 225 904
Percentage of Shares Shorted 1.49%

ADCT Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

ADC Therapeutics SA Logo
ADC Therapeutics SA

Country

Switzerland

Industry

Biotechnology

Market Cap

304.1m USD

Dividend Yield

0%

Description

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

Contact

VAUD
Epalinges
Biopole, route de la Corniche 3B
+41216530200.0
https://adctherapeutics.com/

IPO

-

Employees

312

Officers

CEO & Director
Dr. Ameet Mallik M.B.A., M.S.
Chief Financial Officer
Mr. Jose I. Carmona M.B.A.
Chief Medical Officer
Dr. Mohamed Zaki M.D., Ph.D.
Corporate Controller & Chief Accounting Officer
Ms. Lisa Michelle Kallebo
Chief Technical Operations Officer
Dr. Michael Mulkerrin Ph.D.
Chief Scientific Officer
Dr. Patrick van Berkel Ph.D.
Show More
Investor Relations Officer
Amanda Hamilton
Chief Legal Officer
Mr. Peter J. Graham Esq.
Vice President of Investor Relations & Corporate Communications
Ms. Eugenia Litz
Senior VP & Chief People Officer
Ms. Kimberly Pope
Show Less

See Also

Discover More
What is the Intrinsic Value of one ADCT stock?

The intrinsic value of one ADCT stock under the Base Case scenario is 5.86 USD.

Is ADCT stock undervalued or overvalued?

Compared to the current market price of 3.16 USD, ADC Therapeutics SA is Undervalued by 46%.